Copyright
©The Author(s) 2021.
World J Immunol. Jul 24, 2021; 11(1): 1-10
Published online Jul 24, 2021. doi: 10.5411/wji.v11.i1.1
Published online Jul 24, 2021. doi: 10.5411/wji.v11.i1.1
Table 1 Summary of different advanced therapy medicinal products approved by the European Medicines Agency with their approval date and withdrawal date, if applicable
| Advanced therapy medicinal products | ||||||||
| Gene therapies | EC approval | Withdrawal | Cell therapies | EC approval | Withdrawal | Tissue-based therapies | EC approval | Withdrawal |
| Glybera | Oct-12 | Oct-17 | Provenge | Sept-13 | May-15 | MACI | Jun-13 | Sept-14 |
| Imlygic | Dec-15 | Zalmoxis | Aug-16 | Feb-20 | Holoclar | Feb-15 | ||
| Strimvelis | May-16 | Alofisel | Mar-18 | Spherox | Jul-17 | |||
| Kymriah | Sept-18 | Chondrocelect | Oct-09 | Jan-17 | ||||
| Yescarta | Sept-18 | |||||||
| Luxturna | Nov-18 | |||||||
| Zynteglo | Jun-19 | |||||||
| Zolgensma | Mar-20 | |||||||
- Citation: García-González J, Marhuenda-Castillo S, Romero-Carretero S, Beltrán-García J. New era of personalized medicine: Advanced therapy medicinal products in Europe. World J Immunol 2021; 11(1): 1-10
- URL: https://www.wjgnet.com/2219-2824/full/v11/i1/1.htm
- DOI: https://dx.doi.org/10.5411/wji.v11.i1.1
